1. Home
  2. MSD vs AARD Comparison

MSD vs AARD Comparison

Compare MSD & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

N/A

Current Price

$7.26

Market Cap

146.9M

Sector

Finance

ML Signal

N/A

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

N/A

Current Price

$5.95

Market Cap

165.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MSD
AARD
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.9M
165.8M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
MSD
AARD
Price
$7.26
$5.95
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$15.29
AVG Volume (30 Days)
42.2K
113.1K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
11.26%
N/A
EPS Growth
N/A
43.11
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.91
$3.35
52 Week High
$7.94
$17.94

Technical Indicators

Market Signals
Indicator
MSD
AARD
Relative Strength Index (RSI) 50.62 46.41
Support Level $7.23 $5.12
Resistance Level $7.44 $6.43
Average True Range (ATR) 0.06 0.80
MACD 0.00 -0.13
Stochastic Oscillator 27.79 33.48

Price Performance

Historical Comparison
MSD
AARD

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: